Literature DB >> 18558875

Vaccines: correlates of vaccine-induced immunity.

Stanley A Plotkin1.   

Abstract

The immune system is redundant, and B and T cells collaborate. However, almost all current vaccines work through induction of antibodies in serum or on mucosa that block infection or interfere with microbial invasion of the bloodstream. To protect, antibodies must be functional in the sense of neutralization or opsonophagocytosis. Correlates of protection after vaccination are sometimes absolute quantities but often are relative, such that most infections are prevented at a particular level of response but some will occur above that level because of a large challenge dose or deficient host factors. There may be >1 correlate of protection for a disease, which we term "cocorrelates." Either effector or central memory may correlate with protection. Cell-mediated immunity also may operate as a correlate or cocorrelate of protection against disease, rather than against infection. In situations where the true correlate of protection is unknown or difficult to measure, surrogate tests (usually antibody measurements) must suffice as predictors of protection by vaccines. Examples of each circumstance are given.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558875     DOI: 10.1086/589862

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  349 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

3.  Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Authors:  Megan K L MacLeod; Amy S McKee; Alexandria David; Jieru Wang; Robert Mason; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

4.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

5.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

Review 6.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

7.  Environmental exposures are hidden modifiers of anti-viral immunity.

Authors:  Anthony M Franchini; B Paige Lawrence
Journal:  Curr Opin Toxicol       Date:  2018-01-31

Review 8.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

9.  The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.

Authors:  Peter D Crompton; Marko Mircetic; Greta Weiss; Amy Baughman; Chiung-Yu Huang; David J Topham; John J Treanor; Iñaki Sanz; F Eun-Hyung Lee; Anna P Durbin; Kazutoyo Miura; David L Narum; Ruth D Ellis; Elissa Malkin; Gregory E D Mullen; Louis H Miller; Laura B Martin; Susan K Pierce
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.